COVID-19 Updates

Date: March 21, 2022 Issue #: 1646Summary: The CDC has issued new guidance allowing for an interval of up to 8 weeks between the first and second primary doses of an mRNA COVID-19 vaccine in certain patients 12-64 years old.1 Product labeling currently recommends a 3-week interval between the first two doses of the Pfizer/BioNTech mRNA vaccine(Comirnaty) and a 4-week interval between the first two doses of the Moderna mRNA vaccine(Spikevax). The new guidance is based on data suggesting that a longer interval can decrease the risk of myocarditis and may improve vaccine efficacy.

http://secure.medicalletter.org/TML-article-1646d

Source: The Medical Letter - March 4, 2022 Category: Drugs & Pharmacology Authors: admin Tags: cilgavimab Comirnaty COVID-19 Evusheld Spikevax tixagevimab vaccines Source Type: research